Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neuromuscular Blocking Agents vs Sedation in Severe COVID-19 ARDS
NCT04922814Completed
- Sponsor
- Assiut University
- Start
- Aug 2021
- Primary completion
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Trial of cisatracurium in coronavirus disease 2019 (COVID-19) and acute respiratory distress syndrome (ARDS) (2 arms), sponsored by Assiut University. Primary endpoint: Ratio of arterial oxygen partial pressure to fractional inspired oxygen at 48 hours. Started Aug 2021; status: completed.
02
Drugs
cisatracurium
03
Conditions
coronavirus disease 2019 (COVID-19)acute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on NCT04922814.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04922814.